A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2018
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Entinostat (Primary) ; Docetaxel; Gemcitabine; Irinotecan; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Apr 2017 Status changed from active, no longer recruiting to discontinued.
- 03 May 2016 Status changed from recruiting to active, no longer recruiting.
- 13 Jul 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.